Abstract: Rapidly progressing proteomics techniques have been widely adopted in most areas of biology and medicine. In neurology and neuroscience, many applications of proteomics have involved neurotoxicology and neurometabolism, as well as in the determination of specific proteomic aspects of individual brain areas and body fluids in neurodegeneration. Investigation of brain protein groups in neurodegeneration, such as enzymes, cytoskeleton proteins, chaperones, synaptosomal proteins and antioxidant proteins, is in progress as phenotype related proteomics. The concomitant detection of several hundred proteins on a gel provides sufficiently comprehensive data to determine a pathophysiological protein network and its peripheral representatives. The rapid spread of proteomics technology, which principally consists of twodimensional gel electrophoresis (2-DE) with in-gel protein digestion of protein spots and identification by massspectrometry, has provided an explosive amount of results. An additional advantage is that hitherto unknown proteins have been identified as brain proteins. The current proteomics methods, however, have shortcomings and disadvantages. We would emphasize the failure to separate hydrophobic proteins as a major problem. So far, we have been unable to analyze the vast majority of these proteins in gels on 2-DE. There are several other analytical problems which also need to be overcome, and once solved, will allow for a more comprehensive analysis of the individual disease process. Here, we have reviewed the recent progress in proteomics research on neurodegeneration, with reference to its technological utility and problems in clinical application.
INTRODUCTION
Neurodegenerative diseases are central nervous system disorders characterized by progressive neuronal cell loss and intraneuronal accumulation of fibrillary materials. Abnormal protein-protein interactions may allow the precipitation of these proteins, forming intracellular and extracellular aggregates. These abnormal interactions could play a role in the dysfunction and neuronal death that characterizes several common neurodegenerative diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD).
A number of mechanisms appear to be involved in the neurodegenerative process, including alterations in calcium homeostasis in the endoplasmic reticulum, which contribute to neuronal apoptosis, excitotoxicity and unregulated proteolysis. Mitochondrial dysfunction may also be linked to neurodegenerative disease through free radical generation, impaired calcium buffering and the mitochondrial permeability transition. Both apoptosis and necrotic cell death are observed in neurodegenerative diseases. Another possible mechanism is the disorganization of the cytoskelton leading to neuronal degeneration.
ALZHEIMER'S DISEASE
Alzheimer's disease (AD) is defined by the clinicopathological features of its irreversible and progressive course: neuronal cell death, and accumulation of aggregated *Address correspondence to this author at the Department of Neurology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharcho, Sakyoku, Japan; proteins such as amyloid or tau. These pathological changes are identified predominantly in certain regions of the brain such as the temporo-parietal cortex and hippocampus. A unique feature of AD compared to other neurodengerative diseases, such as Parkinson , s disease, cerebellar degeneration or motor neuron disease, is that it has several risk factors. There has been a long discussion about minerals as risk factors for AD, and aluminum is still a strong candidate (Forbes and McLachlan, 1996) . It has been reported that head trauma with unconsciousness may be a risk factor for the disease (Guo et al., 2000) . The Apo E allele 4 is well known as a risk factor for AD and is itself toxic to cultured neurons (Marques and Crutcher, 2003) . Recently, cohort research in patients with hypertension or hypercholesterolemia indicated that agents such as calcium blockers (Forette et al ., 2002) and statins (Zamrini et al., 2004) might have a preventative effect on the development of AD. Aging is, however, the greatest risk factor among those identified so far in AD. As people grow older, they are more likely to develop AD. Although AD can strike people in their 30s, 40s, or 50s, the vast majority of cases of AD are diagnosed in people older than 65. What is it about the aging process that makes a person more likely to develop AD? One logical way for researchers to tackle this question is to study various populations of people to learn what is different about the people who develop AD compared with those who do not. Key phenomena in hypothetic cascades of the mechanism of AD pathophysiology are amyloid aggregation, tau phosphorylation, paired helical filament (PHF) and tangle formation, amyloid precursor protein (APP) accumulation, energy metabolism, cholinergic neuronal cell damage and cell death. Although these unidirectional schemes represent the pro-gressive and irreversible aspect of AD, many protective circuits putting the break on this deterioration must be active in living cells not only in normal aging but also in AD. Genetic disorder can provide much data about this, and the existence of familial AD is another unique feature of this disease.
As both familial and sporadic AD show almost the same clinical and pathological phenotype, we considered that AD is an appropriate disease in which construction of the genomic, proteomic, and phenomic database might elucidate the complicated flux underlying the disease process.
GENOME AND PROTEOME
During the last few years, considerable efforts have focused on genomic studies and large-scale DNA-sequencing projects. The ultimate goal of these studies is to define the genome, the human genome in particular, with the hope of being able to identify and study key genes functional in both normal and aberrant pathways in diseases.
Rapid development in protein research is expected after completion of the human genome sequence. However, proteins are not merely the downstream expressions of genes. Protein levels are affected by the balance of their generation, modification and degradation under systematic stimuli or the influence of homeostasis, processes more complicated than simply gene information.
The proteome, which was named following the rationale of the "genome", is the big theme of future life science research. Accumulation of proteomic data will change research methods significantly in association with progress in bioinformatics. However, the proteome database cannot be completed easily. The database continues to expand as the data are available. The application of the proteome database to the research of various diseases is likely, especially now in the post genome era.
In contrast to the genome, which represents attributes fixed and unaltered during lifetime, the proteome is expressed as a constant state of protein metabolism. Comparative studies to identify, quantitate, and characterize the proteins expressed in normal versus diseased cells will give insight into the mechanisms of pathogenesis.
Several problems, however, need to be overcome to construct a comprehensive proteome database. The first of these is the most essential; brain tissue is a heterogeneous sample consisting of neurons, glia, vessels etc., so that detection of a change in proteins might represent not only a pathological neuronal process but also a glial reaction or be a reflection of neuronal cell loss as a simple result of neurodegeneration. The second problem is the sensitivity of detection. As described in several published papers, the number of translated proteins is estimated at approximately 40,000 in individual cells. We could detect, at most, 3,000 protein spots from brain tissue, which is far less than expected. Another problem is the inability to isolate less soluble membrane proteins and low abundant proteins. For these reasons we consider that the proteome project is much more complicated compared with the genome project. In this review, after a brief overview of proteomics technology, the proteomics in neurodegenerative diseases are divided into three segments: detection of disease specific alterations in protein expression in brain tissue, identification of marker proteins through the analysis of alteration of proteomic aspects in body fluids, and subproteome in several conditions (e.g. transgenic animals and cell lines transfected with disease related genes) for the detection of specific proteomic alteration.
PROTEOMIC APPROACH AND TOOLS
Classical proteomics for profiling or mapping experiments employs mass spectrometers to measure mass to charge ratio or to identify peptide sequences; typically, the proteins are subjected to some form of separation (e.g. 2-DE, SDS-PAGE, liquid chromatography), and then cleaved enzymatically to generate the constituent peptides. However, it is becoming increasingly common for the entire protein mixture to be digested with a protease and the resultant peptide pool analyzed (Peng and Gygi, 2001 ). In either case, the resulting peptides can be analyzed by a variety of mass spectrometers that are capable of performing one of two ionization techniques: matrix assisted laser desorption ionization (MALDI), or electrospray ionization (ESI). MALDIor ESI-MS experiments allow measurement of peptide mass, while MALDI-or ESI-tandem MS experiments allow the determination of the mass of peptide ion fragments that represent the sequence of the peptide. Both methods use software-assisted database searches. Consequently, if the peptide sequence can be derived or if the corresponding mass can be measured accurately, the unknown parent protein can be identified by one of the aforementioned search methods. In the next subsections, we will discuss the initial phase of most proteomic analyses, resolution of complex protein mixtures by separation and digestion, which will be followed by a discussion of instrumentation.
PROTEIN SEPARATION AND DIGESTION
The most common protocol for proteomic analysis is protein separation by 2-DE followed by "in-gel" digestion where a specific spot is removed from the gel and then incubated with trypsin or another protease. The protein digest can then be isolated from the gel matrix and the resulting peptides subjected to MS. A similar protocol for blotted protein digestion can be used for proteins that have been separated by one-or two-dimensional (2-DE) PAGE and then transferred to nitrocellulose or polyvinylidenedifluoride (PVDF) membranes.
A single 2-DE gel electrophoresis can resolve up to thousands of proteins and has been the predominant separation method used in proteomic analysis. Although this technique underwent several modifications in the early 1970s, the basic separation principles developed by O'Farrell (1975) , remain unchanged; i.e. resolution of proteins by charge (isoelectric focusing, IEF) in the first dimension followed by separation by size (SDS-PAGE) in the second dimension. While proteins separated by 2-DE can be visualized by conventional staining methods including silver, Coomassie Brilliant Blue and Amido black stains, the development of fluorescent stains (SYPRO Ruby; Berggren et al., 2000) has improved linearity, while reducing the interference with mass spectrometric analysis that has been associated with other staining methods (e.g. silver staining). With advances in technology, 2-DE is still a powerful tool for resolving highly complex protein mixtures.
There are significant analytical challenges for 2-DE. Isoelectric focusing as the first dimension is technically difficult, which has led to problems with reproducibility. However, 2-DE systems have been developed that use immobilized pH gradient (IPG) strips for IEF and a simplified system for the transfer of proteins from the strips into the second dimension SDS-PAGE system. There is, however, still room for improvement for the analysis of membrane bound proteins, proteins with high molecular weight, very basic or very acidic proteins. Moreover, low abundance proteins are undetectable without pre-gel enrichment (Gygi et al., 2000) . However, improved solubilization techniques for membrane bound proteins have been developed using mixtures of CHAPS, urea and thiourea (Luban and Goff, 1995, Shiozaki et al., 2004) . In addition, the use of IPG IEF strips has improved the analysis of acidic and basic proteins.
DETERMINATION OF PEPTIDE MASS BY SPEC-TROMETRY
Peptides can be analyzed by either MALDI-MS or ESI-MS, or by tandem MS. For peptide mass fingerprinting, the predominant method used is MALDI-time-of-flight (TOF), whereas ESI-tandem MS is most commonly employed for peptide fragment ion analysis. All mass spectrometers all have some basic components or regions: a source that generates peptide ions, a mass analyzer, which separates ions based on their mass/charge (m/z) ratio, and an ion detector.
MALDI-TOF instruments offer several advantages. They are easy to use and, when interfaced with new robotic sample preparation devices, have a relatively high throughput capacity. These instruments are also very sensitive; i.e. accurate mass measurements can be made on femtomole quantities. However, MALDI-TOF usually provides peptide mass information only and there is significant limitation since peptide sequence information is required when the genome of interest has not been fully sequenced or when working with protein mixtures or limited sample amounts. In addition, the sample quality is a critical determinant for successful measurement of peptide mass using the MALDI-TOF systems. Detergents, metal contaminants, salts and organic additives (e.g. dithiothreitol) can interfere with peptide ionization and thereby reduce sensitivity. However, in general MALDI-TOF systems are recognized as excellent analytical tools for proteomic measurement.
The other commonly used ionization process is ESI (Fenn et al., 1989) . A modification to an amino acid residue, such as phosphorylation or chemical adduction, is indicated by a characteristic shift in the mass of the precursor ion and by corresponding shifts in the b-and y-ions containing the predicted modified residue. Obviously, a peptide fragment ion (MS/MS) spectrum relays a myriad of information that may be interpreted to identify any sequence or corresponding modification. Fortunately, several data-reduction algorithms and software are available to process the uninterpreted spectral data; e.g. SEQUEST program, SALSA algorithm and MASCOT program.
NEW PROTEOMICS TECHNIQUES

1) Detection Technologies in Proteome Analysis
Two-dimensional gel electrophoresis is a long established technology where proteins are separated according to their isoelectric point (pI) and molecular weight (Mr). The 2-DE technology is often criticized due to perceived difficulties in execution, lack of reproducibility and limited proteome coverage. To this end, alternative techniques such as multidimensional LC, CE and HPLC-CE techniques coupled with MS/MS have been developed for proteomics, e.g. the MudPIT approach , Liu et al., 2002 . These approaches are frequently preceded by enzymatic digestion of the entire protein sample to yield a complex peptide mixture, which can overcome some solubility problems. It is claimed that these techniques allow enhanced identification of low abundance and/or membrane proteins (Liu et al., 2002) . However, the number of peptides produced vastly increases the sample complexity and places huge demands on the peptide separation and analysis system. Poor resolution can prevent successful protein identification. The ICAT (isotope coded affinity tag) technique developed by Aebersold et al., (1998) follows the principle of biotin labeling of cysteine containing peptides and their affinity capture using avidin. This reduces sample complexity considerably, improving the resolution of peptides by HPLC, but also incorporates heavy and light mass tags, which allows quantitative protein expression analysis between samples (Zhang et al., 2001 , Oda et al., 2003 , Wu et al., 2003 . However, multiple samples must always be analyzed to ensure the statistical validity of results and this increases the processing time and the demands on the reproducibility of the chromatography. In addition, obtaining information on protein post-translational modification and processing using ICAT remains challenging. Despite significant and ever increasing developments in multidimensional LC such as those above, it is likely that 2-D PAGE still has the edge in terms of its ability to resolve and quantify complex protein mixtures. With 2-D PAGE, hundreds to thousands of proteins and post-translational modifications can be readily detected and analyzed.
Two dimensional difference gel electrophoresis (DIGE) enables the analysis of multiple protein samples within one gel (Unlu et al., 1997 , Tonge et al., 2001 . This is achieved through the covalent modification of each protein with structurally distinct fluorophores. The images from samples separated on the same gel can be overlaid and directly compared. This process reduces the gel-to-gel variability and raises the confidence with which protein differences can be detected and quantified, as one channel can effectively be used to run an internal standard which is a pool of all the samples being analyzed. However, due to the nature of the minimal labeling of lysine residues, where approximately 5% of a given protein is labeled, spots cannot be directly excised for mass spectrometry (MS) analysis and detection sensitivity could be further enhanced following staining with another MS compatible protein stain and excision of the entire spot. Saturation labeling of proteins with second sets of CyDye DIGE Cy 3 and Cy5 dyes aims to overcome these limitations through saturation labeling of cystein residues. The saturatrion-labeling dyes were superior in sensitivity to their minimal-labeling counterparts, silver stain and Sypro Ruby, but the resulting 2-D spot pattern was significantly altered from that of unlabelled or minimal-labeled protein.
2) Arrays and Chips
Recently developed techniques are available that do not require initial protein separation methods (e.g. 2-DE, column chromatography). The total protein can now be determined using high-density antibody arrays that directly or indirectly bind cellular proteins (Cahill, 2001 , Figeys, 2002 . Recently marketed arrays (e.g. Clontech, Panomics) bind and, consequently, separate proteins through the use of immobilized antibodies on chips. Bound proteins are identified by prior fluorescent dye labeling, typically with Cy3 or Cy5. A variation of this technique uses a dual antibody strategy that requires one antibody to bind a specific protein, with detection by a labeled secondary antibody. In addition to defining proteomic expression, protein-to-protein interactions can also be determined by array analysis. Although determining the expression of thousands of proteins is the principle advantage of array technology over more conventional proteomic approaches (Cahill, 2001) , there are certain limitations to be considered. The antibody, or protein ligand, must be fixed to the chip and must be retained in a biologically active state. Moreover, care must be taken to avoid denaturing the protein. Overcoming these technical difficulties, protein and antibody arrays continue to develop and will eventually become a valuable tool for investigations (Mitchell, 2002) .
Another approach is ProteinChip™ technology (Ciphergen Biosystems). Each "chip" contains 8 or 16 different affinity surfaces per array, which selectively capture subsets of proteins from extracts. The chemical nature of these affinity surfaces (hydrophobic, cationic or anionic), will, therefore, capture proteins that have complimentary chemical characteristics. Regardless of the specific or general intent of the chip, immobilized proteins are then identified using surfaceenhanced laser desorption/ionization (SELDI)-TOF MS to generate a mass spectrum for each protein. SELDI profiles a subset of proteins distinct from those separated by 2-DE and is most appropriate for low molecular weight components (Craven and Banks, 2001) . Analysis with SELDI produces a series of mass peaks for each affinity matrix, effectively a protein/peptide signature. By using different types of support, it is possible to analyze different subsets of proteins. The technique has been used in various studies, and is particularly suited to the analysis of diagnostic biomarkers in plasma or CSF. Cystatin C has been identified in CSF as a marker of chronic pain (Mannes et al., 2003) . Beta amyloid has been identified in the lens of AD patients, suggesting that pathological features of the disease overlap between the brain and lens (Goldstein et al., 2003) as well as in CSF (Lewczuk et al., 2003) and serum (Bradbury et al., 2004) . In spite of the limitation of SELDI to the analysis of peptide and proteins of less than 20 kDa, SELDI is more suitable to high throughput prescreening and identification of the presence of differentially expressed proteins.
Proteomic analysis of the brain is complicated by the need to obtain cells from specific anatomical regions, or nuclei. Laser capture micro dissection (LCM) is a technique that is precise enough to dissect single cells within a tissue section, and thus could be useful for isolating specific brain nuclei for analysis. Laser micro dissection (LMD) represents a breakthrough technology that allows rapid procurement of selected homogenous populations of intact cells from sections of complex, heterogeneous tissue, thus focusing on individual genes or proteins from a particular subset of cells. In 1996, Emmert-Buck et al., (1996) first described LMD and this technique has since become a widely used technique in the world of genomics (Fend et al., 1999 , Goldsworthy et al., 1999 , Parlato et al., 2002 . LMD is an easy, extremely fast and versatile method for the isolation of morphologically or immunohistochemically defined cell populations. This, combined with the ability to visually confirm the nature of the captured material, is a great advantage of this technique. The precision of microdissection, however, depends on the ability to distinguish specific cell types. Unfortunately, one disadvantage of laser microdissection is that it is necessary to use dehydrated sections in the absence of a cover slip. This leads to a significant decrease in the optical resolution, which may alter the ease of this technique and require the employment of various staining techniques.
Different staining methods have been investigated with down-stream 2-D gel electrophoresis by Craven and Banks (2002) , Mouledous et al., (2003b) and Ahram et al., (2003) and unstained method of LMD was applied in brain proteomics (Mouledous et al., 2003a) . The combination of LMD and proteomics provides a powerful tool in studying the underlying changes in normal and diseased states, and has the potential to lead to the identification of new molecular markers and potential therapeutic targets.
PROTEOMIC ASPECTS OF BRAIN TISSUE IN NEURODEGENERATIVE DISEASES
Proteomic analysis data has become an important resource in the investigation of neurodegenerative diseases. Proteomic profiling, in particular, has enabled researchers to investigate a vast number of proteins at once. Such principles have been utilized in order to detect specific alterations in the protein expression levels in various regions of the AD brain compared to control brain. This may, in turn, facilitate the construction of hypotheses of the mechanisms by which the disease progresses.
1) Alzheimer's Disease
Proteome Profiling of Brain Proteins in AD
Since proteomic analysis using 2-DE enables the investigation of a large number of proteins at a time, it is an efficient tool for research on the disease process in "multifactorial" AD. There have been several reports about the proteomic analysis of AD brains (Korolain en et al., 2002 , Schonberger et al., 2001 , Tsuji et al., 1999 , Shiozaki et al., 2004 .
We performed proteome analysis on AD brain proteins, which had been sequentially extracted using two distinct sample preparation solutions. In the first step, the brain sample was homogenized with lysis buffer containing SDS, which is a strong detergent for the solubilization of proteins and also an efficient reagent for the high resolution of 2-DE gels (Herbert, 1999 , Tsuji et al., 1999 . Since a large amount of SDS is not compatible with steady-state IEF, due to its ionic nature, the first extracts, designated as fraction A, were made after dilution with a sample solution containing urea and NP-40. In the second step, the proteins not solubilized in the first extraction, designated as fraction B, were homogenized with SDS lysis buffer, following dilution with a sample solution containing urea, thiourea, SB3-10 and CHAPS. We analyzed the proteomic changes in both fractions A and B in the same brains (Fig. 1) . In this way, a large number of proteins were isolated, and we compared the protein expression between AD and control groups. This method enabled us to obtain 2-DE data with high resolution and excellent reproducibility, and will contribute to the enhancement of the AD brain proteome database. After performing 2-DE on these two fractions separately, we obtained high-resolution 2-DE data showing 1283 spots on the fraction A reference gel, and 531 spots on the fraction B reference gel. We compared the difference in protein expression between AD and control groups. The analysis revealed that the %VOL of 18 spots was significantly different in AD and control brains. The proteins identified can be divided into several groups including enzymes, molecular chaperones, cytoskeletal proteins and other proteins (Fig. 2) . To our knowledge, the following proteins have not been reported in AD brains; isocitrate dehydrogenase 3 (NAD + ), guanine deaminase, heat shock protein 70-2 (HSP70-2), mu-crystallin and SH3 domain binding glutamic acid-rich protein like protein (SH3BGRL) (Shiozaki et al., 2004) .
Proteins Altered in AD
Contrasting with the proteomic investigation on brain proteins in AD, a large body of work has been reported on the altered expression of a number of proteins by comparison Fig. (1) . The sequential extraction of brain proteins procedure: Brain tissues were homogenized with SDS lysis buffer consisting of 125 mM Tris-HCl (pH 6.8), 2 % SDS, 20 % glycerol and 2 % mercaptoehanol. The first extract (fraction A) was collected after dilution with the sample solution containing urea/NP40 and centrifugation. The pellet was homogenized with the same SDS lysis buffer and boiled. After dilution with the sample solution containing urea/thiourea/SB3-10/CHAPS and centrifugation, the supernatant was collected (fraction B). based mainly on immunoreactivity data and not by screening an entire set of proteins at one time. In addition to the pathophysiological hallmarks of the disease, which are well documented, AD is associated with an alteration of proteins involved in synapse loss (Qin et al., 2004 , Greber et al., 1999 , Porchet et al., 2003 , Schuller et al., 2001 , Cheon et al., 2001 , Bajo et al., 2001 , Shim and Lubec, 2002 ), cholinergic neurons (Engidawork et al., 2001a) , energy metabolism (Schonberger et al., 2001) , decreased glucose metabolism (Mattson et al., 2001) , and glial reaction (Greber et al., 1999 , Tsuji et al., 1999 . Oxidative stress and mitochondrial function deficits, increased protein misfolding and decreased protein degradation and apoptosis are thought to be key processes significantly involved in AD. An increase in carbonyl reductase (CBR), alcohol dehydrogenase (ADH), peroxiredoxin-I (Prx-I), peroxiredoxin-II (Prx-II), antioxidant protein 2, and Cu/Zn superoxide dismutase was detected (Balcz et al., 2001 , Schonberger et al., 2001 , Krapfenbauer et al., 2003 . Moreover, a decrease in peroxiredoxin-III (Prx-III), metallothionein-1 (MT-1), and metallothionein-3 (MT-3) expression was found , Prange et al., 2001 . Fig. (2) . The list shows the full names and %VOL ratio (AD/control) of the proteins whose %VOL was changed in AD brains compared with control brains: Quantitative analysis of spots was carried out using % VOL. Significant differences between AD and control groups was evaluated using Student's t -test (P <0.05). The proteins identified can be divided into several groups including enzymes, molecular chaperones, cytoskeletal proteins and other proteins. The underlined proteins have not been reported in AD brains; isocitrate dehydrogenase 3 (NAD + ), guanine deaminase, heat shock protein 70-2 (HSP70-2), mu-crystallin and SH3 domain binding glutamic acid-rich protein like (SH3BGRL).
Of apoptotis related proteins, zipper-interacting protein kinase (ZIPK), Bcl-2-interacting mediator of cell death/Bcl-2 related ovarian death gene (Bim/BOD), and the receptor interacting protein (RIP)-like interacting CLARP kinase (RICK) were found to be increased in AD brains (Engidawork et al., 2001b) . The anti-apoptotic protein Bcl-2 is also up regulated in the cerebellum only from the AD brain (Engidawork et al ., 2001b) . The alterations in expression of many proteins involved in a number of pathways help to develop testable hypotheses of neurodegenerative mechanisms in AD, which brings enrichment of information in phenotype related protein pathology (AD phenomics).
2) Parkinson's Disease
Parkinson's disease (PD) is a devastating and complex disorder that progressively affects the control of movement. Its cardinal clinical features include resting tremor, rigidity, bradykinesia, gait dysfunction and postural instability. PD is characterized by the gradual loss of dopaminergic neurons in the substantia nigra pars compacta, and by the intracytoplasmic accumulation of proteinaceous inclusions in the form of Lewy bodies and Levy neuritis. Given the biochemical and neuropathological changes reminiscent of those occurring in sporadic PD, 1methyl-1,2,3,6-tetrahydropyridine (MPTP), its active metabolite 1-methly-4-phenylpyridinium (MPP + ) and 6-hydroxydopamine (6-OHDA) have been widely utilized to induce the selective death of dopaminergic neurons in both in vivo and in vitro culture models of PD. From such studies, several factors have been implicated in the pathogenesis of PD. These include oxidative stress, mitochondrial impairment, excitotoxicity, increased levels of free cytosolic calcium and inflammatory processes. In addition, it was demonstrated recently that familial cases of PD are caused by mutations in the genes that encode alpha-synuclein, parkin and ubiquitin carboxyterminal hydrolase L1. However, a growing body of evidence is beginning to indicate that the accumulation of altered proteins and impaired protein clearance may be common mechanisms in the pathogenesis of both familial and sporadic PD. More specifically, it is believed that impairment of the ubiquitin-proteasome system appears to be involved directly in the process of dopaminergic neuronal cell death. It has been demonstrated, for example, that parkin has an E3 ligase activity and that this is involved in the ubiquitin/proteasome pathway for misfolded proteins. While other proteins such as alpha-synuclein, synphilin, ubiquitin, ubiquitin carboxy-terminal hydrolase L1, neurofilament and tau have been detected in Lewy bodies in PD, many more proteins must be identified in order to fully explain the direct role of abnormal protein aggregates in the pathogenesis of PD on proteomic investigation (Basso et al., 2003) .
3) Proteomic Aspects of Body Fluids in Neurodegenerative Diseases
For AD research using proteomics, the brain is not the only tissue that has been examined in order to elicit protein expression changes. Blood plasma samples have been examined for apolipoprotein E (ApoE), tau, and presenilin 2 in order to develop a less invasive screening process for AD (Ueno et al., 2000) . Cerebral spinal fluid (CSF) has also been used to determine differences between control and AD patients (Davidsson et al., 2002b) . Several significant protein expression changes were determined in this study, including a decrease in the isoforms of ApoE and pro-apolipoprotein, suggesting that there may be a decrease in the levels of these proteins in the brain as well.
Pathologies involving increased neuronal loss and/or impaired synaptogenesis may result in disease-specific alterations of neuronal and CSF proteins and are well suited for proteomic analysis. Synaptic pathology has been implicated in several psychiatric disorders, including Alzheimer's disease and schizophrenia. A recent analysis of the synaptic proteins in human CSF exemplifies the utility of this approach in the study of synaptic function and pathology in living subjects. The expression of many synaptic proteins is altered in schizophrenia and AD, providing important insights into disease pathology and opportunities for better differential diagnosis. Other examples of disease specific proteins characterized in the CSF from patients with neurological disorders are summarized in a review (Rohlff, 2000) .
Despite the evidence that AD is a distinctive disorder with identifiable neuropathological features, accurate clinical diagnosis of AD remains a challenge. The initial symptoms of AD occur on a continuum with normal age-related memory loss, making AD difficult to identify in its earliest stages. Overlap of the symptoms of AD with those of other neurodegenerative dementing disorders further complicates its differential diagnosis. Autopsy studies remain the gold standard for confirming an AD diagnosis. No single antemortem diagnostic test has been developed that permits identification of AD with comparable accuracy to autopsy. The inability to reliably diagnose AD during life has implications beyond the diagnostic domain. Without an objective marker of the onset of AD, administration of available pharmacological treatment is often delayed for months or years from time of first symptoms. Lack of an objective biological measure for AD onset and progression also limits our ability to assess the effectiveness of potential new therapies in clinical trials. These difficulties have delayed the development of more effective AD treatments and preventatives, and in other ways undermine the clinical management of patients with AD. While significant progress has been made in the identification and characterization of some of the molecules involved in AD's causal pathways, no single laboratory test yet identified permits accurate and reliable ante-mortem diagnosis. In past studies, a large number of putative AD diagnostic markers have been identified in brain, blood, CSF, fibroblasts, urine and other tissue products. There is evidence to suggest that certain CSF proteins (e.g., Tau, Abeta42, and AD7c-NTP) can be useful adjuncts in the clinical diagnosis of AD. Among clinically demented patients, elevated Tau, decreased Abeta42 and possession of the epsilon4 allele of APOE support an AD diagnosis. Another proposed AD diagnostic measures the expression of AD7c-NTP in CSF or urine. Unfortunately, the sensitivity and specificity of all of the above-mentioned markers, either alone or in combination, is insufficient to merit routine clinical use. The failure of past approaches to molecularbased AD diagnosis may be related to AD's inherently multifactorial nature. It has been estimated that only 2% of human diseases are the result of a single gene defect. AD is a complex genetic disorder arising from the interaction of multiple genes and environmental factors. In this context, there may be particular merit in the use of approaches that simultaneously assay multiple biologic markers and their interactions. Choe et al., (2002) demonstrated that multiple approaches might be useful in a study that identified nine molecular markers that segregated AD from normal controls. Johnson et al., (1992) reported the results of a comparative 2-DE analysis study in the CSF in AD. In this study, one isoform of alpha-2 haptoglobin was identified and this protein was reduced in both AD and schizophrenia. Davidsson et al., (2002a) indicated that the intensity of 10 protein spots was altered in AD CSF compared to the controls. The levels of six proteins and their isoforms, including proapolipoprotein, apolipoprotein E, beta-2 microglobulin, retinal-binding protein, transthyretin, and uibquitin, were significantly altered and the most prominently altered proteins were apolipoprotein, especially proapolipoprotein. Puchades et al., (2003) detected 15 protein spots that were increased or reduced two fold in AD compared to controls, 7 of which were identified and included alpha-2-HS glycoprotein, transthyretin, alpha1beta glycoprotein, alpha-2-HS glycoprotein, alpha-1 antitrypsin precursor, transferring precursor, albumin, and beta-2 microglobulin. In frontotemporal dementia (FTD), Davidsson et al., (2002a) documented quantitative differences in the expression of CSF proteins in patients with FTD compared to controls in a two-dimensional gel based proteomic study, including granin-like neuroendocrine precursor, pigment-epithelium derived factor, retinal-binding protein, apoE, haptoglobin, and albumin..
One of the reasons for the difficulty in isolating low abundance biomarkers from serum or plasma is the fact that a small number of proteins such as albumin, alpha2-microglobulin, transferrin, and immunoglobulins, may represent as much as 80% of the total serum protein. The large quantity of these proteins makes it difficult to identify low abundance proteins in serum using traditional 2-dimensional electrophoresis. To resolve the problem, a combination of multidimensional liquid chromatography and gel electrophoresis coupled to matrix-assisted laser desorption/ionizationquadruople-time of flight and ion trap liquid chromatography-tandem mass spectrometry has been used to identify protein markers in the sera of patients with AD. Zhang et al., (2001) identified 5 serum proteins, including the 10 kDa subunit of vitronectin, alpha 1-acid glycoprotein, apolipopro- Fig. (3) . Typical silver-stained image of 2-DE gels of fraction A. The %VOL of 15 spots was significantly changed in AD brains compared with control brains. All of these proteins, pointed on the gel, were identified using MS. tein B100, fragment of factor H, and histidine-rich glycoprotein, which were altered in AD. The biological meaning of the proteomic changes in the disease states and the potential use of these changes as diagnostic tools or for therapeutic intervention will be determined.
SUBPROTEOMIC ANALYSIS
The application of proteomics has recently shown its versatility in studying specific proteins, the function of which may play an important role in the pathological mechanism of neurodegeneration in disease. Studies already published have described the screening of protein expression and protein oxidation in AD, but these are not the only target of neuroproteomics. Recently, several studies have applied the techniques of electrophoresis, coupled with mass spectrometry, to specific enzymes in order to identify their role, their mechanism of action and their relationship with other proteins in the brain. A literature search has identified a few studies that have applied proteomics to AD brain proteins, although some investigations report the inconvenient necessity of isolating the protein of interest from the AD brain.
A number of these studies have concentrated on the proteomic analysis of specifically modified samples such as low soluble and hydrophobic brain proteins, glycoproteins, oxidized proteins and phosphorylated proteins. These subproteomics have also been applied to transfected cell lines and animal models. These complementary databases are important in constructing a comprehensive proteome database. In AD, proteomic techniques such as 2D gel electrophoresis and mass spectrometry analysis have been combined with the immunochemical detection of protein carbonyls, a marker of protein oxidation, to identify specifically oxidized proteins in AD brains . These approaches to identify specifically oxidized proteins in AD brains have been complemented by the work of Choi (2002) , who identified oxidized proteins in AD plasma. In addition, a method for the identification of oxidized proteins in AD brains has been recently described, although the actual identification of oxidized proteins was not provided (Korolainen et al., 2002) . The detection of markers of oxidation in AD brains clearly shows the importance of oxidative stress in the progression of the disease, (Butterfield et al., 2001 . However, evidence on how some proteins are more affected by oxidation in AD and, consequently, are more prone to inactivation, would provide a significant step in linking well-established AD neurodegeneration with oxidative events at the protein level.
Identification of proteins containing reactive carbonyl groups in AD and control brain samples can be determined by 2D Oxyblot analysis. Comparison of 2D Oxyblots with images of Coomassie Blue-stained 2D gels from the same samples revealed that many, but not all, individual protein spots in brain extracts from the inferior parietal lobule (IPL) exhibit anti-protein carbonyl immunoreactivity . Two dimensional Oxyblots and the subsequent 2D gel images have been matched and the anti-DNP immunoreactivities of individual proteins separated by 2D PAGE were normalized to their content, obtained by measuring the intensity of colloidal Coomassie Blue staining. This procedure allows comparison of the oxidation levels of brain proteins in AD versus control subjects. The first use of proteomics to identify oxidized proteins in AD brains led to the identification of several specifically oxidized proteins: creatine kinase BB, glutamine synthase, ubiquitin carboxy-teminal hydrolase L-1, and dihydropyrimidinase related protein 2 . A plausible mechanism of neurodegeneration in the AD brain can be generated based on each of these specifically oxidized proteins. Moreover, some of the pathological characteristics of AD brains, such as the accumulation of aggregated, damaged proteins, excess ubiquinatin, and shortened dendritic length are consistent with the putative dysfunction of some of these specifically oxidized proteins Castegna et al., 2003) . The expression of peroxiredoxins (Prxs), a recently characterized family of highly conserved antioxidant enzymes, and other antioxidant enzymes in the frontal cortex and cerebellum of Downs syndrome, AD and PD patients was investigated using the technique of proteomics (Krapfenbauer et al., 2003) .
Liquid chromatography/tandem MS (LC/MS/MS) has been used recently to characterize the phosphopeptides and the corresponding phosphorylated motifs found in high molecular weight neurofilament subunit proteins (NFH) isolated from the post-mortem cervical spinal cord of patients with sporadic amyotrophic lateral sclerosis (ALS) (Strong et al., 2001) . The results showed that the phosphorylated amino acid residues identified in ALS NFH were also phosphorylated in NFH from normal human spinal cord samples. This suggests that NFH in ALS are not aberrantly phosphorylated and that the neurofilamentous aggregates that characterize ALS neuropathology are not composed of hyperphosphorylated NFH subunits. Recently the use of a combination of fluorodye for phosphorylated proteins and MS analysis enabled us to identify phosphorylated proteins on 2-D gels, which provides an efficient tool for the investigation of abnormal phosphorylation in AD brains.
The proteome of a neuron or other cell type is dynamic and is constantly responding to various internal and external stimuli by altering the expression of proteins and by posttranslational modifications of the expressed proteins. Comparative proteomic approaches generally involve two-dimensional polyacrylamide gel electrophoresis with analysis of protein spot patterns or LC-MS with detection of isotopetagged proteins.
DATA ANALYSIS OF PROTEOMICS
Proteomic studies mainly use two-dimensional electrophoresis for protein separation and mass spectrometry for protein identification. In common with genetic microarray analysis, however, there is a need to comprehend the meaning of the vast amount of data that 2-DE experiments produce. Most proteome studies use univariate analysis to compare the levels of a protein spot in a cohort of diseased tissue samples compared with normal tissues. A newer approach is a refinement of multivariate analysis whereby expression levels of many proteins are compared simultaneously. Various methods, such as the neural network and fuzzy logic have been proposed for this type of analysis (Alaiya et al., 2002) . The software package ProPeak (3Z Informatics) is used to compute and rank the contribution of each individual peak toward the optimal separation of two diagnostic groups. ProPeak implements the linear version of the Unified Maximum Separability Analysis (UMSA) algorithm that was first reported for use in microarray data analysis. The key feature of the UMSA algorithm is the incorporation of data distribution information into a structural risk minimization learning algorithm to identify a direction along which the two classes of data are best separated. This direction is represented as a linear combination (weighted sum) of the original variables. The weight assigned to each variable in this combination measures the contribution of the variable toward the separation of the two classes of data.
PROTEIN NETWORK MAPPING
We now know that multimeric protein complexes mediate most major cellular processes. Moreover, in carrying out their biological functions, these large protein assemblies interact with other large complexes. In essence, the cell can be viewed as a miniature factory that is composed of individual protein machines arranged into interlocking assembly lines that manufacture products or execute various cellular functions (Alberts, 1998, Staley and Guthrie, 1998) . Clearly, adduct formation of proteins with toxic chemicals could disrupt subsequent interactions with other proteins and/or the formation of multiprotein complexes. To identify the protein components of selected complexes and discern the impact of toxicants on their formation, two basic approaches are available: yeast two-hybrid systems and immunoprecipitation "pull-down" procedures.
Pull-down studies involve immunoprecipitation of a protein, which will, in turn, precipitate associated (interactive) proteins. Precipitated proteins are then separated by one-dimensional PAGE and are electrophoretically transferred to a membrane, which is subsequently immunoprobed for suspected interacting proteins. This type of pull-down Fig. (4) . Typical silver-stained image of 2-DE gels of fraction B: The %VOL of three spots significantly increased in AD brains compared with control brains. Two of these spots were identified as GFAP using MS. experiment has been used to examine the interactions of SNARE proteins (syntaxin 1a, SNAP-25, synaptobrevin) during synaptic vesicle docking (e.g., see Pevsner et al., 1994) . Immunoprecipitation can also be effectively combined with MS techniques to identify components of multiprotein complexes. Generally, immunoprecipitation is used to pull down a target and its interacting proteins. Proteins are then separated by one-dimensional PAGE and digested in-gel. MALDI-TOF and peptide mass fingerprinting are used to identify individual protein components. This approach works best for less complex protein mixtures. For more complex mixtures, immunopreciptated proteins can be subjected to proteolysis and the resulting peptides identified by LC/tandem MS.
CONCLUSION
The application of proteomics to the investigation of neurological diseases started a few years ago. The 2-D databases mainly comprise general images of the total brain and of the major subcellular fractions of the brain. Many changes in the levels and modification of, mainly, abundant brain proteins have been detected by proteomics technologies, and the information thus obtained is essential for the further study of the brain and of neurodegenerative diseases. This task may be difficult, and demands technological improvement such as an increase in sensitivity and performance of the analytical methods and, in particular, the detection and visualization of certain protein classes, such as low-abundance and hydrophobic proteins. In addition, we should remember that transfer of data between the transcriptome and proteome is not straightforward, and that there is an increasing need for focused proteomic approaches at the structural, quantitative, cell biological and phenomic levels.
We have no predictive tools for AD. We also have no monitoring methods for the course of the disease. Several analytical problems need to be overcome, but there is nothing to stop the development of a method for the largescale analysis of comprehensive proteomic mode in neurodegenrative disorders. 
